William Blair on Viking Therapeutic (VKTX) Sell-Off: 'extreme and unwarranted'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Raymond James Reiterates Strong Buy Rating on Viking Therapeutic (VKTX), PT $122
August 19, 2025 2:10 PM EDTRaymond James analyst Steve Seedhouse reiterated a Strong Buy rating and $122.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Viking reported topline data from its Phase 2 study evaluating oral VK2735 in obesity showing dose-dependent weight loss over 13 weeks reaching reductions of up to 12.2% (10.9% placeboadjusted, p... More
Morgan Stanley Reiterates Overweight Rating on Viking Therapeutic (VKTX)
August 19, 2025 1:20 PM EDTMorgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $98.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Oral VK2735 weigh loss above the ~8% bar at the highest dose (120mg: 12.2%) and inline/above at lower doses (30mg/60mg: 7.0%/8.7%).... More
Jefferies on Viking Therapeutic (VKTX): 'We think the market is overreacting'
August 19, 2025 1:17 PM EDTJefferies analyst Roger Song reiterated a Buy rating and $101.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Bottom line. We think the market is overreacting on GI AE/ discontinuation profile, underappreciating that it could be modulated by dosing optimization ("start low, go... More
H.C. Wainwright Keeps PT at $102 on Viking Therapeutic (VKTX), 'Varying Sentiments Flying Around, But We Are Happy
August 19, 2025 12:13 PM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $102.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Phase 2 oral VK2735 delivers encouraging weight loss; market focus shifts to tolerability and competition. This morning, Viking announced positive topline results from its Phase 2 VENTURE-Oral Dosing Trial of oral VK2735 for weight loss. While we view the weight loss results as encouraging (see topline data below) and see the tolerability profile as something that can be optimized in future trials, we want to highlight a few contributing factors that we believe... More
Stifel on Viking Therapeutic (VKTX) Sell-Off: 'an over-reaction to the successful Ph.2 VENTURE-Oral (13-week) outcome'
August 19, 2025 12:09 PM EDTStifel analyst Samimy Annabel reiterated a Buy rating and $95.00 price target on Viking Therapeutic (NASDAQ: VKTX)
The analyst comments "We reiterate our Buy on VKTX, $95 TP following what we think is an over-reaction to the successful Ph.2 VENTURE-Oral (13-week) outcome,... More
